Well, hello, everyone. We're very excited to be here today to talk about the latest Alzheimer's

disease drug that slowed down the rate of cognitive decline in a phase three clinical trials

in early Alzheimer's disease. We're always excited to hear any breakthrough.

I mean, even though we've had so many failures and letdowns, to us, it's about life and death

because we see it in our clinic every single day.

I think we've seen more than 15,000 patients,

patients with mild cognitive impairment with memory disorders,

patients with early dementia.

So many patients where we, for the first time,

tell them what they have, the diagnosis.

And to me, it never gets easy. It's the most difficult

conversation. It's the most taxing, most troublesome, most anxiety to it, not just for the patient

and family, for me, but I cherish the opportunity to be there to tell them the story in a way that's,

you know,

keeps their dignity,

empowers them to some extent,

takes the worries a little bit as much as we can,

although it's a degenerative disease.

And where we,

where we can do something something if it's early enough

you know intervene with lifestyle and and make a difference but a great number of patients we

really can't I mean lifestyle has been shown to affect even Alzheimer's patients but never reversing

...